Quality & complianceOfficial

MHRA publishes October 2026 advertising investigation decisions, including weight-loss treatment services

🇬🇧 MHRA · Wed 04 Nov 2026

The UK regulator has released decisions on adverts reported as breaching medicines advertising law, with documents covering weight-loss services and websites offering medicinal treatment services.

The Medicines and Healthcare products Regulatory Agency (MHRA) published its October 2026 advertising investigation decisions on 4 November 2026. The decisions concern adverts that were reported as having breached the legislation on advertising medicines.

Two documents accompany the release. One is titled "Medicinal treatment services for weight loss" and the other "Websites offering medicinal treatment services". Both are published in HTML format. The page itself does not set out the individual outcomes, so details of the cases sit in those linked documents.

The MHRA invites anyone with concerns about medicines advertising to contact its Advertising Standards Unit by email at advertising@mhra.gov.uk or by post at 10 South Colonnade, Canary Wharf, London E14 4PU. It also points to the two industry self-regulatory bodies: the Proprietary Association of Great Britain (PAGB) for over-the-counter medicines advertising, and the Prescription Medicines Code of Practice Authority (PMCPA) for promotion of prescription medicines to health professionals.

The agency also refers readers to the Blue Guide for guidance on how medicines should be promoted or advertised in the UK. As context, the Blue Guide is the MHRA's long-standing reference document on UK medicines advertising rules.

What it means for your team

  • Promotional compliance teams should read the two linked decision documents in full, as the summary page does not detail the outcomes.
  • Companies and service providers involved in weight-loss treatment services or websites offering medicinal treatment services should check their materials against the published decisions.
  • Check the Blue Guide and the relevant self-regulatory route (PAGB for OTC, PMCPA for prescription medicines to health professionals) when reviewing advertising concerns.

Official source: MHRA ↗

Article written by VigiEye from the official source (MHRA). AI-assisted; check the source before acting.

More Quality & compliance All →